NY-ALKEGEN
Alkegen, a leading specialty materials platform creating transformational battery materials, today announced they will be exhibiting at the upcoming AABC Europe Conference in Mainz, and The Battery Show Europe in Stuttgart, Germany. Alkegen’s Battery Group focuses on delivering battery innovation with advanced materials for Lithium Ion Battery (LiB) thermal barriers and electrical protection, battery separator technology, and revolutionary silicon fiber anode battery material (SiFAB®) that enables greater energy density, faster charges, and longer battery life in electric vehicles, portable electronics and energy storage systems. Alkegen, formerly Unifrax and Lydall, is a one-of-a-kind specialty materials platform dedicated to human health and sustainability.
The technical capabilities of the Alkegen Battery Group support customer partnerships with a global engineering team, deep technical expertise, and customer collaboration. These unique capabilities allow for a globally coordinated team of engineers and designers with a dedicated presence in each region, solutions designed for easy installation and handling, and scalable, customized solutions that meet budgets and optimize performance.
Alkegen’s range of technical capabilities includes Design, Testing, Prototyping and Serial Production. The global design team employs 3D modelling software to collaborate with customers and optimize form, fit and function. Thermal, mechanical, environmental and compression testing are used for part validation and new product development. The engineering team prototypes both in-pack and in-cell solutions once designed to validate product functionality. Finally, Alkegen’s global footprint of IATF certified sites and engineering teams support scale up through regional production locations in Europe, North America and the Asia-Pacific region.
Alkegen’s transformational battery portfolio includes both in-cell and in-pack solutions. In-cell solutions such as separators and additives to improve cell performance and safety include SiFAB, Alkegen’s fibrous silicon anode battery material with ultra-high capacity that enables greater energy density and is highly scalable. SiFAB technology was launched last year and will scale to production this summer. Also from Alkegen, Inovion™ is a high surface area fibrous separator paper that promotes rapid ion exchange. Alkegen also offers several in-pack solutions including high-temperature lightweight products designed to reduce thermal runaway propagation along with providing mechanical, electrical and thermal protections within the battery pack. Innovative product solutions also include FyreBlocker™ LiB, AlkeGel™ Aerogel Materials and FyreWrap® LiB performance materials. These in-cell and in-pack innovations have valuable functions in numerous industries and applications from portable electronics, e-mobility, to robotics.
”Alkegen’s Battery Group is focused on delivering the latest battery technologies and developments from our long-standing tradition of innovating unique material technologies to create superior new products and solutions for our customers’ greatest challenges,” explained Adam Kelsall, General Manager, Alkegen Battery Group. “This transformational portfolio presents numerous opportunities for Alkegen with applications spanning EV lithium-ion battery fire protection, creating greater battery energy density and delivering longer battery life in both electric vehicles and consumer electronics,” said Kelsall.
Alkegen will be available to discuss these innovative new battery materials and more during the 2022 AABC Europe Show June 13-15, in Mainz, and The Battery Show June 28-30, in Stuttgart, Germany. Interested attendees can sign up for sessions with our Alkegen Battery Group experts to meet during the conferences by contacting us at info@alkegen.com .
About Alkegen
Alkegen, formerly Unifrax and Lydall Materials, creates high performance specialty materials used in advanced applications including electric vehicles, energy storage, filtration, fire protection and high-temperature insulation, among many others. Alkegen is vertically integrated across multiple process technology platforms designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our mission of helping the world breathe easier, live greener and go further than ever before. Alkegen has 75 manufacturing facilities operating in 12 countries and employs 9,000+ employees globally. More information is available at www.alkegen.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608006046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom